| 2026-04-29 |
财报披露：
美东时间 2026-04-29 盘前发布财报
|
| 2026-03-31 |
股东大会：
将于2026-05-28召开股东大会
会议内容 ▼▲
- 1.Director Election
2.Advisory Vote on Compensation of Named Executive Officers
3.Appointment of Independent Registered Public Accounting Firm
|
| 2026-03-31 |
股东大会：
将于2026-05-28召开股东大会
会议内容 ▼▲
- 1.Director Election
2.Advisory Vote on Compensation of Named Executive Officers
3.Appointment of Independent Registered Public Accounting Firm
|
| 2026-03-31 |
详情>>
股本变动：
变动后总股本116440.32万股
|
| 2026-03-17 |
详情>>
内部人交易：
Sabag Mark股份减少62102.00股
|
| 2026-02-03 |
详情>>
业绩披露：
2025年年报每股收益1.23美元,归母净利润1.41亿美元,同比去年增长108.60%
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.81美元,归母净利润9.30亿美元,同比去年增长165.40%
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益0.43美元,归母净利润4.97亿美元,同比去年增长150.46%
|
| 2025-05-07 |
详情>>
业绩披露：
2025年一季报每股收益0.19美元,归母净利润2.14亿美元,同比去年增长253.96%
|
| 2025-04-09 |
股东大会：
将于2025-06-05召开股东大会
会议内容 ▼▲
- 1.Election of Directors;
2.Advisory Vote on Compensation of Named Executive Officers;
3.Approval of Teva’s Amended Compensation Policy;
4.Approval of an Amendment to the Terms of Office and Employment of Teva’s President and Chief Executive Officer;
5.Approval of an Amendment to Director Compensation;
6.Appointment of Independent Registered Public Accounting Firm
|
| 2025-04-09 |
股东大会：
将于2025-06-05召开股东大会
会议内容 ▼▲
- 1.Election of Directors;
2.Advisory Vote on Compensation of Named Executive Officers;
3.Approval of Teva’s Amended Compensation Policy;
4.Approval of an Amendment to the Terms of Office and Employment of Teva’s President and Chief Executive Officer;
5.Approval of an Amendment to Director Compensation;
6.Appointment of Independent Registered Public Accounting Firm
|
| 2025-02-05 |
详情>>
业绩披露：
2024年年报每股收益-1.45美元,归母净利润-16.39亿美元,同比去年增长-193.2%
|
| 2025-02-05 |
详情>>
业绩披露：
2022年年报每股收益-2.2美元,归母净利润-24.46亿美元,同比去年增长-686.57%
|
| 2024-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.91美元,归母净利润-10.22亿美元,同比去年增长9.72%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.26美元,归母净利润-14.22亿美元,同比去年增长-39.14%
|
| 2024-07-31 |
详情>>
业绩披露：
2024年中报每股收益-0.87美元,归母净利润-9.85亿美元,同比去年增长9.72%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-0.12美元,归母净利润-1.39亿美元,同比去年增长36.82%
|
| 2024-04-16 |
股东大会：
将于2024-06-06召开股东大会
会议内容 ▼▲
- 1.To appoint the following persons to Teva’s Board of Directors: Prof.Varda Shalev to serve as a director until Teva’s 2026 annual meeting of shareholders,and Rosemary A.Crane,Gerald M.Lieberman and Prof.Ronit Satchi-Fainaro to serve as a director until Teva’s 2027 annual meeting of shareholders,
2.To approve, on a non-binding advisory basis, the compensation for Teva’s Teva’s 2026 annual meeting of shareholders.
3.To recommend,on a non-binding advisory basis,to hold a non-binding,advisory vote to approve the compensation for Teva’s named executive officers every one,two or three years.
4.To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2025 annual meeting of shareholders.
|
| 2024-04-16 |
股东大会：
将于2024-06-06召开股东大会
会议内容 ▼▲
- 1.To appoint the following persons to Teva’s Board of Directors: Prof.Varda Shalev to serve as a director until Teva’s 2026 annual meeting of shareholders,and Rosemary A.Crane,Gerald M.Lieberman and Prof.Ronit Satchi-Fainaro to serve as a director until Teva’s 2027 annual meeting of shareholders,
2.To approve, on a non-binding advisory basis, the compensation for Teva’s Teva’s 2026 annual meeting of shareholders.
3.To recommend,on a non-binding advisory basis,to hold a non-binding,advisory vote to approve the compensation for Teva’s named executive officers every one,two or three years.
4.To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2025 annual meeting of shareholders.
|
| 2024-02-12 |
详情>>
业绩披露：
2023年年报每股收益-0.5美元,归母净利润-5.59亿美元,同比去年增长77.15%
|
| 2023-04-19 |
股东大会：
将于2023-06-15召开股东大会
会议内容 ▼▲
- 1.To appoint the following persons to Teva’s Board of Directors: Dr. Sol J. Barer, Michal Braverman-Blumenstyk and Janet S. Vergis to serve until Teva’s 2026 annual meeting of shareholders.
2.To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers.
3.To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2024 annual meeting of shareholders.
|
| 2023-04-19 |
股东大会：
将于2023-06-15召开股东大会
会议内容 ▼▲
- 1.To appoint the following persons to Teva’s Board of Directors: Dr. Sol J. Barer, Michal Braverman-Blumenstyk and Janet S. Vergis to serve until Teva’s 2026 annual meeting of shareholders.
2.To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers.
3.To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2024 annual meeting of shareholders.
|
| 2022-04-13 |
股东大会：
将于2022-06-23召开股东大会
会议内容 ▼▲
- 1.To appoint the following persons to Teva’s Board of Directors: Amir Elstein, Roberto A. Mignone, Dr. Perry D. Nisen and Dr. Tal Zaks to serve until our 2025 annual meeting of shareholders.
2.To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers.
3.To approve Teva’s Compensation Policy with respect to the terms of office and employment of Teva’s Executive Officers and Directors, substantially in the form attached as Appendix A to this Proxy Statement.
4.To approve Amendments to Teva’s Articles of Association, as reflected in the form attached as Appendix B to this Proxy Statement.
5.To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2023 annual meeting of shareholders.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-21 |
股东大会：
将于2021-06-14召开股东大会
会议内容 ▼▲
- 1.To appoint the following persons to Teva’s Board of Directors: Rosemary A. Crane, Abbas Hussain, Gerald M. Lieberman and Prof. Ronit Satchi-Fainaro to serve until our 2024 annual meeting of shareholders.
2.To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers.
3.To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2022 annual meeting of shareholders.
|
| 2020-04-22 |
股东大会：
将于2020-06-09召开股东大会
会议内容 ▼▲
- 1.To appoint the following persons to the Board of Directors: Dr. Sol J. Barer, Jean-Michel Halfon, Nechemia (Chemi) J. Peres and Janet S. Vergis to serve until our 2023 annual meeting of shareholders.
2.To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers.
3.To approve Teva’s 2020 Long-Term Equity-Based Incentive Plan, substantially in the form attached as Appendix A to this Proxy Statement.
4.To approve an amendment to the terms of office and employment of Teva’s President and Chief Executive Officer.
5.To approve an amendment to Teva’s Articles of Association
6.To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2021 annual meeting of shareholders.
|
| 2019-04-16 |
股东大会：
将于2019-06-11召开股东大会
会议内容 ▼▲
- 1.To appoint the following persons: Amir Elstein, Roberto A. Mignone and Dr. Perry D. Nisen to serve on the Board of Directors until our 2022 annual meeting of shareholders.
2.To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers.
3.To approve an amended Compensation Policy with respect to the terms of office and employment of Teva’s Executive Officers and Directors, substantially in the form attached as Appendix A to this Proxy Statement.
4.Director Compensation:
(a)To approve the compensation to be provided to Teva’s non-employee directors;
(b)To approve the compensation to be provided to Teva’s non-executive Chairman of the Board.
5.To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2020 annual meeting of shareholders.
|
| 2018-04-25 |
股东大会：
将于2018-06-05召开股东大会
会议内容 ▼▲
- 1.To appoint the following persons to the Board of Directors: Rosemary A. Crane, Gerald M. Lieberman and Prof. Ronit Satchi-Fainaro as directors to serve until our 2021 annual meeting of shareholders.
2.To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers.
3.To recommend, on a non-binding advisory basis, to hold a non-binding, advisory vote to approve the compensation for Teva’s named executive officers every one, two or three years.
4.To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until the 2019 annual meeting of shareholders.
5.To approve an amendment and restatement of Teva’s 2008 Employee Stock Purchase Plan for U.S. Employees.
|
| 2017-11-02 |
除权日：
美东时间 2017-11-27 每股派息0.09美元
|
| 2017-08-03 |
除权日：
美东时间 2017-08-25 每股派息0.09美元
|
| 2017-06-08 |
股东大会：
将于2017-07-13召开股东大会
会议内容 ▼▲
- 1. To appoint the following persons to the Board of Directors: Dr. Sol J. Barer, Mr. Jean-Michel Halfon, Mr. Murray A. Goldberg and Mr. Nechemia (Chemi) J. Peres as directors to serve until our 2020 annual meeting of shareholders, and Mr. Roberto Mignone and Dr. Perry D. Nisen as directors to serve until our 2019 annual meeting of shareholders.
2. To approve the compensation of Dr. Sol J. Barer as Chairman of the Board of Directors.
3. To approve the terms of office and employment of Dr. Yitzhak Peterburg as Interim President and Chief Executive Officer.
4. To approve a membership fee for directors serving on special or ad-hoc committees.
5. To approve an amendment to the 2015 Long-Term Equity-Based Incentive Plan to increase the number of shares available for issuance thereunder.
6. To approve Teva’s 2017 Executive Incentive Compensation Plan.
7. To reduce Teva’s registered share capital to NIS 249,434,338, by canceling 424,247 Ordinary “A” Shares, par value NIS 0.1 per share and 5,232,377 ordinary shares, par value NIS 0.1 per share and to make corresponding amendments to Teva’s Memorandum of Association and Articles of Association.
8. To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until the 2018 annual meeting of shareholders.
|
| 2017-05-16 |
除权日：
美东时间 2017-06-01 每股派息0.29美元
|
| 2017-02-15 |
除权日：
美东时间 2017-02-28 每股派息0.34美元
|
| 2016-11-15 |
除权日：
美东时间 2016-12-01 每股派息0.34美元
|
| 2016-08-08 |
除权日：
美东时间 2016-08-18 每股派息0.29美元
|
| 2016-05-11 |
除权日：
美东时间 2016-05-20 每股派息0.29美元
|
| 2016-02-16 |
除权日：
美东时间 2016-02-25 每股派息0.29美元
|
| 2015-10-30 |
除权日：
美东时间 2015-11-13 每股派息0.34美元
|
| 2015-07-31 |
除权日：
美东时间 2015-08-18 每股派息0.34美元
|
| 2015-05-04 |
除权日：
美东时间 2015-05-15 每股派息0.34美元
|
| 2015-02-05 |
除权日：
美东时间 2015-02-17 每股派息0.34美元
|
| 2014-10-30 |
除权日：
美东时间 2014-11-13 每股派息0.32美元
|
| 2014-07-31 |
除权日：
美东时间 2014-08-19 每股派息0.35美元
|
| 2014-05-01 |
除权日：
美东时间 2014-05-16 每股派息0.35美元
|
| 2014-02-07 |
除权日：
美东时间 2014-02-20 每股派息0.34美元
|
| 2013-10-31 |
除权日：
美东时间 2013-11-18 每股派息0.33美元
|
| 2013-08-01 |
除权日：
美东时间 2013-08-16 每股派息0.32美元
|
| 2013-05-03 |
除权日：
美东时间 2013-05-16 每股派息0.32美元
|
| 2013-02-07 |
除权日：
美东时间 2013-02-19 每股派息0.31美元
|
| 2012-11-05 |
除权日：
美东时间 2012-11-13 每股派息0.26美元
|
| 2012-08-03 |
除权日：
美东时间 2012-08-13 每股派息0.25美元
|